Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: The key Alzheimer’s disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid Aβ 42 and p-tau 181), or poorly specific (atrophy on MRI and hypometabolism on fluorodeoxyglucose-PET). Recently developed plasma biomarkers could significantly enhance the efficiency of the diagnostic pathway in memory clinics and improve patient care. This study aimed to: (1) confirm the correlations between plasma and traditional AD biomarkers, (2) assess the diagnostic accuracy of plasma biomarkers as compared with traditional biomarkers, and (3) estimate the proportion of traditional exams potentially saved thanks to the use of plasma biomarkers. Methods: Participants were 200 patients with plasma biomarkers and at least one traditional biomarker collected within 12 months. Results: Overall, plasma biomarkers significantly correlated with biomarkers assessed through traditional techniques: up to r=0.50 (p<0.001) among amyloid,r=0.43 (p=0.002) among tau, and r=−0.23 (p=0.001) among neurodegeneration biomarkers. Moreover, plasma biomarkers showed high accuracy in discriminating the biomarker status (normal or abnormal) determined by using traditional biomarkers: up to area under the curve (AUC)=0.87 for amyloid, AUC=0.82 for tau, and AUC=0.63 for neurodegeneration status. The use of plasma as a gateway to traditional biomarkers using cohort-specific thresholds (with 95% sensitivity and 95% specificity) could save up to 49% of amyloid, 38% of tau, and 16% of neurodegeneration biomarkers. Conclusion: The implementation of plasma biomarkers could save a remarkable proportion of more expensive traditional exams, making the diagnostic workup more cost-effective and improving patient care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 1×
“22 Amyloid-PET positivity was visually assessed by an expert in nuclear medicine physician (VG, > 15 years of experience in the field) using visual assessment and standard operating procedures approved from the European Medicines Agency.”
MethodKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationBlood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Self-citationAssociations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626 · cited 1×
“The over-representation of MCI patients allows us to generalise our results to a wider memory clinic population undergoing biomarker testing (as MCI patients are the ones who might benefit the most from biomarker testing 3 ).”
Self-citationComparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545 · cited 1×
“40 (3) Specific strategies need to be developed to minimise the impact of errors.”
BackgroundSelf-citationPerformance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465 · cited 1×
“37 (2) An optimisation of operating procedures and assay reproducibility should be achieved, with a detailed protocol for the handling of plasma AD biomarkers and a cross-validation across laboratories, in analogy with what has been already achieved for CSF markers.”
Method
Cited by
Boccalini, C., Ribaldi, F., Hristovska, I., Arnone, A., Peretti, D. E., Mu, L., Scheffler, M., Perani, D., Frisoni, G. B., & Garibotto, V. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13355 · Cited by 82
Self-citationThe potential clinical value of plasma biomarkers in Alzheimer's disease
Blennow, K., Galasko, D., Perneczky, R., Quevenco, F., van der Flier, W. M., Akinwonmi, A., Carboni, M., Jethwa, A., Suridjan, I., & Zetterberg, H. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13455 · Cited by 75
“72 Implementation studies should be undertaken to gather evidence on how plasma biomarker testing can be incorporated in various different clinics and contexts and to examine the most effective ways to useplasmabiomarkertestinginclinicalsettings.”
BackgroundSelf-citationHeyer, S., Simon, M., Doyen, M., Mortada, A., Roch, V., Jeanbert, E., Thilly, N., Malaplate, C., Kearney-Schwartz, A., Jonveaux, T., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01535-3 · Cited by 14
Metadata
- Authors
- Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., Lathuiliere, A., Scheffler, M., Ashton, N. J., Zetterberg, H., Blennow, K., Kern, I., Frias, M., Garibotto, V., & Frisoni, G. B.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2023-04-03
- Volume
- 94
- Issue
- 6
- Pages
- 420-427
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W4362522071
- Cited by
- 62
- References
- 15
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic. https://app.cochat.ai/papers/10.1136/jnnp-2022-330619
- The paper
- Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., Lathuiliere, A., Scheffler, M., Ashton, N. J., Zetterberg, H., Blennow, K., Kern, I., Frias, M., Garibotto, V., & Frisoni, G. B. (2023). Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2022-330619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.